Giannasca Paul J, Warny Michel
Acambis Inc., 38 Sidney Street, Cambridge, MA 02139, USA.
Vaccine. 2004 Feb 17;22(7):848-56. doi: 10.1016/j.vaccine.2003.11.030.
Clostridium difficile, a gram-positive bacterium, is the major cause of hospital-acquired infectious diarrhea and colitis in industrialized nations. C. difficile colonization results from antibiotic administration and subsequent loss of protection provided by intestinal flora. C. difficile induced-colitis is caused by the release of two exotoxins, toxin A and B. Host factors including advanced age, pre-existing severe illness and weakened immune defenses predispose individuals to symptomatic infection. The generation of antibody responses to toxin A through natural exposure is associated with protection from disease. In addition, an inability to acquire immunity to toxin A puts individuals at risk for recurrent and/or severe disease. Immunological approaches for the management of this disease are being developed which could reduce the reliance on antibiotics for treatment and allow for re-establishment of the natural barrier provided by an intact commensal flora. An active vaccine and various immunotherapeutic strategies under evaluation may prove to be effective against severe or relapsing C. difficile infection.
艰难梭菌是一种革兰氏阳性菌,是工业化国家医院获得性感染性腹泻和结肠炎的主要病因。艰难梭菌的定植源于抗生素的使用以及随后肠道菌群所提供保护作用的丧失。艰难梭菌诱导的结肠炎是由两种外毒素,即毒素A和毒素B的释放所引起的。宿主因素包括高龄、既往存在的严重疾病以及免疫防御功能减弱,这些因素使个体易发生有症状的感染。通过自然暴露产生针对毒素A的抗体反应与预防疾病相关。此外,无法获得对毒素A的免疫力会使个体面临复发和/或严重疾病的风险。正在研发针对该疾病的免疫治疗方法,这可能会减少对抗生素治疗的依赖,并有助于重建由完整共生菌群提供的天然屏障。正在评估的一种活性疫苗和各种免疫治疗策略可能被证明对严重或复发性艰难梭菌感染有效。